Causes and treatment outcomes of Stevens-Johnson syndrome and toxic epidermal necrolysis in 82 adult patients

Korean Journal of Internal Medicine

Volumn 27, Issue 2, 2012, Pages 203-210

  Kim, Hye In ^a   Kim, Shin Woo ^a   Park, Ga Young ^a   Kwon, Eu Gene ^a   Kim, Hyo Hoon ^a   Jeong, Ju Young ^a   Chang, Hyun Ha ^a   Lee, Jong Myung ^a   Kim, Neung Su ^a  

^a Kyungpook National University School of Medicine   (South Korea)

Author keywords

Epidermal necrolysis; Etiology; Prognosis; Stevens johnson syndrome; Toxic

Indexed keywords

ALLOPURINOL; ANTIBIOTIC AGENT; ANTICONVULSIVE AGENT; CARBAMAZEPINE; CEFADROXIL; CEPHALOSPORIN; COTRIMOXAZOLE; CYSTEINE; DANTROLENE; DEXAMETHASONE; DIAZEPAM; DOXYCYCLINE; FAMCICLOVIR; HERBACEOUS AGENT; HYDANTOIN; IMMUNOGLOBULIN; LANSOPRAZOLE; LEVOFLOXACIN; MELOXICAM; NAPROXEN; NEUROLEPTIC AGENT; NIMESULIDE; NONSTEROID ANTIINFLAMMATORY AGENT; PENICILLIN G; PHENOBARBITAL; PHENYTOIN; PREDNISOLONE; STEROID; VALPROIC ACID;

ABSENCE OF SIDE EFFECTS; ADULT; ADVERSE OUTCOME; ANEMIA; ARTICLE; CAUSAL ATTRIBUTION; CAUSE OF DEATH; CLINICAL EVALUATION; CLINICAL FEATURE; CONTROLLED STUDY; CORNEA INJURY; DRUG EFFECT; DRUG SAFETY; EYE EDEMA; EYE PAIN; FEMALE; HEMOGLOBIN BLOOD LEVEL; HUMAN; KERATITIS; KIDNEY DYSFUNCTION; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; PHOTOPHOBIA; PNEUMONIA; PROGNOSIS; RETROSPECTIVE STUDY; SEX DIFFERENCE; STEVENS JOHNSON SYNDROME; SYMBLEPHARON; TOXIC EPIDERMAL NECROLYSIS; TREATMENT DURATION; TREATMENT OUTCOME; VISUAL IMPAIRMENT; XEROPHTHALMIA;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; CHI-SQUARE DISTRIBUTION; EPIDERMAL NECROLYSIS, TOXIC; FEMALE; HUMANS; LOGISTIC MODELS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; ODDS RATIO; REPUBLIC OF KOREA; RISK ASSESSMENT; RISK FACTORS; STEVENS-JOHNSON SYNDROME; SURVIVAL ANALYSIS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84862837254     PISSN: 12263303     EISSN: 20056648     Source Type: Journal    
DOI: 10.3904/kjim.2012.27.2.203     Document Type: Article

References (29)

1. Borchers AT, Lee JL, Naguwa SM, Cheema GS, Gershwin ME. Stevens-Johnson syndrome and toxic epidermal necrolysis. Autoimmun Rev 2008;7:598-605.
2. Mockenhaupt M. The current understanding of StevensJohnson syndrome and toxic epidermal necrolysis. Expert Rev Clin Immunol 2011;7:803-813.
3. Bachot N, Roujeau JC. Differential diagnosis of severe cutaneous drug eruptions. Am J Clin Dermatol 2003;4:561-572.
4. Auquier-Dunant A, Mockenhaupt M, Naldi L, et al. Correlations between clinical patterns and causes of erythema multiforme majus, Stevens-Johnson syndrome, and toxic epidermal necrolysis: results of an international prospective study. Arch Dermatol 2002;138:1019-1024.
5. Tay YK, Huff JC, Weston WL. Mycoplasma pneumoniae infection is associated with Stevens-Johnson syndrome, not erythema multiforme (von Hebra). J Am Acad Dermatol 1996;35(5 Pt 1):757-760.
6. Mulvey JM, Padowitz A, Lindley-Jones M, Nickels R. Mycoplasma pneumonia associated with Stevens Johnson syndrome. Anaesth Intensive Care 2007;35:414-417.
7. Leigh IM, Mowbray JF, Levene GM, Sutherland S. Recurrent and continuous erythema multiforme: a clinical and immunological study. Clin Exp Dermatol 1985;10:58-67.
8. Bastuji-Garin S, Fouchard N, Bertocchi M, Roujeau JC, Revuz J, Wolkenstein P. SCORTEN: a severity-of-illness score for toxic epidermal necrolysis. J Invest Dermatol 2000;115:149-153.
9. Schneck J, Fagot JP, Sekula P, Sassolas B, Roujeau JC, Mockenhaupt M. Effects of treatments on the mortality of Stevens-Johnson syndrome and toxic epidermal necrolysis: a retrospective study on patients included in the prospective EuroSCAR study. J Am Acad Dermatol 2008;58:33-40.
10. Power WJ, Ghoraishi M, Merayo-Lloves J, Neves RA, Foster CS. Analysis of the acute ophthalmic manifestations of the erythema multiforme/Stevens-Johnson syndrome/toxic epidermal necrolysis disease spectrum. Ophthalmology 1995;102:1669-1676.
11. Bastuji-Garin S, Rzany B, Stern RS, Shear NH, Naldi L, Roujeau JC. Clinical classification of cases of toxic epidermal necrolysis, Stevens-Johnson syndrome, and erythema multiforme. Arch Dermatol 1993;129:92-96.
12. Rzany B, Mockenhaupt M, Baur S, et al. Epidemiology of erythema exsudativum multiforme majus, Stevens-Johnson syndrome, and toxic epidermal necrolysis in Germany (1990- 1992): structure and results of a population-based registry. J Clin Epidemiol 1996;49:769-773.
13. Chang YS, Huang FC, Tseng SH, Hsu CK, Ho CL, Sheu HM. Erythema multiforme, Stevens-Johnson syndrome, and toxic epidermal necrolysis: acute ocular manifestations, causes, and management. Cornea 2007;26:123-129.
14. Kim EJ, Lee JB, Kwon YH, et al. A clinical study of Stevens- Johnson syndrome and toxic epidermal necrolysis over the last five-year period in the Gwangju-Chonnam area. Korean J Dermatol 2006;44:574-578.
15. Mockenhaupt M, Viboud C, Dunant A, et al. Stevens-Johnson syndrome and toxic epidermal necrolysis: assessment of medication risks with emphasis on recently marketed drugs. The EuroSCAR-study. J Invest Dermatol 2008;128:35-44.
16. Jeung YJ, Lee JY, Oh MJ, Choi DC, Lee BJ. Comparison of the causes and clinical features of drug rash with eosinophilia and systemic symptoms and stevens-johnson syndrome. Allergy Asthma Immunol Res 2010;2:123-126.
17. Wetter DA, Camilleri MJ. Clinical, etiologic, and histopathologic features of Stevens-Johnson syndrome during an 8-year period at Mayo Clinic. Mayo Clin Proc 2010;85:131-138.
18. Revuz J, Penso D, Roujeau JC, et al. Toxic epidermal necrolysis: clinical findings and prognosis factors in 87 patients. Arch Dermatol 1987;123:1160-1165.
19. Correia O, Chosidow O, Saiag P, Bastuji-Garin S, Revuz J, Roujeau JC. Evolving pattern of drug-induced toxic epidermal necrolysis. Dermatology 1993;186:32-37.
20. Stewart MG, Duncan NO 3rd, Franklin DJ, Friedman EM, Sulek M. Head and neck manifestations of erythema multiforme in children. Otolaryngol Head Neck Surg 1994;111(3 Pt 1):236-242.
21. Khoo AK, Foo CL. Toxic epidermal necrolysis in a burns centre: a 6-year review. Burns 1996;22:275-278.
22. Pushker N, Tandon R, Vajpayee RB. Stevens-Johnson syndrome in India-risk factors, ocular manifestations and management. Ophthalmologica 2000;214:285-288.
23. French LE. Toxic epidermal necrolysis and Stevens Johnson syndrome: our current understanding. Allergol Int 2006;55:9-16.
24. Pereira FA, Mudgil AV, Rosmarin DM. Toxic epidermal necrolysis. J Am Acad Dermatol 2007;56:181-200.
25. Kardaun SH, Jonkman MF. Dexamethasone pulse therapy for Stevens-Johnson syndrome/toxic epidermal necrolysis. Acta Derm Venereol 2007;87:144-148.
26. Araki Y, Sotozono C, Inatomi T, et al. Successful treatment of Stevens-Johnson syndrome with steroid pulse therapy at disease onset. Am J Ophthalmol 2009;147:1004-1011.
27. Faye O, Roujeau JC. Treatment of epidermal necrolysis with high-dose intravenous immunoglobulins (IV Ig): clinical experience to date. Drugs 2005;65:2085-2090.
28. Brown KM, Silver GM, Halerz M, Walaszek P, Sandroni A, Gamelli RL. Toxic epidermal necrolysis: does immunoglobulin make a difference? J Burn Care Rehabil 2004;25:81-88.
29. Shortt R, Gomez M, Mittman N, Cartotto R. Intravenous immunoglobulin does not improve outcome in toxic epidermal necrolysis. J Burn Care Rehabil 2004;25:246-255.